Scandal aside, Biogen's Aduhelm sales set to reach $1B next year and $6B+ by 2025: analysts

Despite the ambush of negative press against Biogen’s Aduhelm and the uncertainty around its benefit to patients, there’s still reason to believe the controversial Alzheimer’s treatment will hit blockbuster status next year, analysts predict.

Yes, physicians still have their doubts about Aduhelm’s murky clinical performance, Piper Sandler analysts said in a note to clients. But despite that, evidence indicates they’ll likely prescribe the monthly infusion enough to boost Biogen’s bottom line.